Health TidingsBioCryst Reports Long-Term ORLADEYO Benefits and New Navenibart Data in HAE BioCryst Reports Long-Term ORLADEYO Benefits and New Navenibart Data in HAE Read Post »
Health TidingsGSK Secures Orphan Drug Designations in US and EU for Momelotinib in VEXAS ... GSK Secures Orphan Drug Designations in US and EU for Momelotinib in VEXAS ... Read Post »
Health TidingsCaliway’s CBL-514 Cuts Weight Regain When Added to Tirzepatide in Pre... Caliway’s CBL-514 Cuts Weight Regain When Added to Tirzepatide in Pre... Read Post »
Health TidingsNovartis Reports Positive FORTITUDE Data for Del-Brax in FSHD Novartis Reports Positive FORTITUDE Data for Del-Brax in FSHD Read Post »
Health TidingsTakeda Reports Phase 3 Win for Zasocitinib in Plaque Psoriasis Takeda Reports Phase 3 Win for Zasocitinib in Plaque Psoriasis Read Post »
Health TidingsCASGEVY Extends Durable Clinical Benefit to Children With SCD and TDT CASGEVY Extends Durable Clinical Benefit to Children With SCD and TDT Read Post »
Health TidingsCemsidomide Achieves 53% Response Rate in Phase 1/2 Multiple Myeloma Trial Cemsidomide Achieves 53% Response Rate in Phase 1/2 Multiple Myeloma Trial Read Post »
Health TidingsFDA Delays CAM2029 Approval in Acromegaly Over Manufacturing Issues FDA Delays CAM2029 Approval in Acromegaly Over Manufacturing Issues Read Post »
Health TidingsFDA Grants Priority Review to Roche’s Tecentriq in Early-Stage Colon Canc... FDA Grants Priority Review to Roche’s Tecentriq in Early-Stage Colon Canc... Read Post »
Health Tidings Mergers & AcquisitionsServier, n-Lorem Launch ASO Research Partnership in Rare Neurology Servier, n-Lorem Launch ASO Research Partnership in Rare Neurology Read Post »
Health Tidings Mergers & AcquisitionsNovartis Expands Orionis Partnership in $1.4 Billion Molecular Glue Drug Di... Novartis Expands Orionis Partnership in $1.4 Billion Molecular Glue Drug Di... Read Post »
Health TidingsOno Files VELEXBRU Expansion in Japan for Secondary CNS Lymphoma Ono Files VELEXBRU Expansion in Japan for Secondary CNS Lymphoma Read Post »
Health TidingsWhat Zepbound and Shaquille O’Neal’s Story Reveal About Undiagn... What Zepbound and Shaquille O’Neal’s Story Reveal About Undiagn... Read Post »
Health TidingsEMA Begins Review of Bayer’s Asundexian for Secondary Stroke Prevention EMA Begins Review of Bayer’s Asundexian for Secondary Stroke Prevention Read Post »
Health TidingsFDA Accepts Takeda’s ENTYVIO sBLA for Pediatric Ulcerative Colitis and Cr... FDA Accepts Takeda’s ENTYVIO sBLA for Pediatric Ulcerative Colitis and Cr... Read Post »
Health TidingsBausch Health Secures Key Reimbursement Milestone for PrOKEDI in Canada Bausch Health Secures Key Reimbursement Milestone for PrOKEDI in Canada Read Post »
Health Tidings Mergers & AcquisitionsLilly Signs Potential $1 Billion Alzheimer’s Deal With AlzeCure Lilly Signs Potential $1 Billion Alzheimer’s Deal With AlzeCure Read Post »
Health TidingsTeva Presents New AUSTEDO Data Across the Tardive Dyskinesia Care Continuum Teva Presents New AUSTEDO Data Across the Tardive Dyskinesia Care Continuum Read Post »
Health TidingsNMPA Approves TIVDAK for Recurrent or Metastatic Cervical Cancer NMPA Approves TIVDAK for Recurrent or Metastatic Cervical Cancer Read Post »
Health Tidings Mergers & AcquisitionsGSK Acquires Nuvalent, Adding FDA-Reviewed ROS1 and ALK Inhibitors GSK Acquires Nuvalent, Adding FDA-Reviewed ROS1 and ALK Inhibitors Read Post »
Health TidingsMerck and Gilead Halt Phase 3 KEYNOTE-D46/EVOKE-03 Study Over Missing PFS E... Merck and Gilead Halt Phase 3 KEYNOTE-D46/EVOKE-03 Study Over Missing PFS E... Read Post »
Health TidingsUK Clears Moderna’s mRNA-4194 for Lynch Syndrome Cancer Prevention Study UK Clears Moderna’s mRNA-4194 for Lynch Syndrome Cancer Prevention Study Read Post »
Health Tidings Mergers & AcquisitionsRoche Licenses Nurix’s BTK Degrader Bexobrutideg in Up to $2.3 Billion De... Roche Licenses Nurix’s BTK Degrader Bexobrutideg in Up to $2.3 Billion De... Read Post »
Health Tidings Mergers & AcquisitionsIncyte Bolsters Hematology Growth With $2 Billion Vega Buyout Incyte Bolsters Hematology Growth With $2 Billion Vega Buyout Read Post »
Health TidingsKorlym Cuts HbA1c and Weight in Difficult-to-Control Diabetes Linked to Hyp... Korlym Cuts HbA1c and Weight in Difficult-to-Control Diabetes Linked to Hyp... Read Post »
Health TidingsFDA Review Accepted for Alvotech’s Vedolizumab Biosimilar FDA Review Accepted for Alvotech’s Vedolizumab Biosimilar Read Post »
Health TidingsMazdutide Achieves 18.6% Weight Loss in Adults With Obesity Mazdutide Achieves 18.6% Weight Loss in Adults With Obesity Read Post »
Health TidingsFoundayo Shows Consistent Weight Loss Across Menopause Stages in Phase 3 AT... Foundayo Shows Consistent Weight Loss Across Menopause Stages in Phase 3 AT... Read Post »
Health TidingsNYB.AI Featured in NVIDIA GTC Taiwan 2026 Opening Showcase, Marking Milesto... NYB.AI Featured in NVIDIA GTC Taiwan 2026 Opening Showcase, Marking Milesto... Read Post »
Health TidingsStructure Reports Up to 16.2% Weight Loss With Oral GLP-1 Aleniglipron Structure Reports Up to 16.2% Weight Loss With Oral GLP-1 Aleniglipron Read Post »
Health TidingsVertex Reports Strong ALYFTREK Results in Young Children With Cystic Fibros... Vertex Reports Strong ALYFTREK Results in Young Children With Cystic Fibros... Read Post »
Health TidingsTeva Reports Quality-of-Life Benefits With AUSTEDO in HD Chorea Teva Reports Quality-of-Life Benefits With AUSTEDO in HD Chorea Read Post »
Health TidingsSouth Africa Rolls Out Lenacapavir to Prevent HIV South Africa Rolls Out Lenacapavir to Prevent HIV Read Post »
Health TidingsNICE Endorses AbbVie’s Elahere as First New NHS Therapy in Over 20 Years ... NICE Endorses AbbVie’s Elahere as First New NHS Therapy in Over 20 Years ... Read Post »
Health TidingsMHRA Authorizes Aujemflu for Influenza Prevention in Adults 50+ MHRA Authorizes Aujemflu for Influenza Prevention in Adults 50+ Read Post »
Health TidingsADC Plans FDA Filing After Positive LOTIS-5 Results for ZYNLONTA ADC Plans FDA Filing After Positive LOTIS-5 Results for ZYNLONTA Read Post »
Health TidingsOtsuka Shows VOYXACT Slowed Kidney Function Decline in IgA Nephropathy Otsuka Shows VOYXACT Slowed Kidney Function Decline in IgA Nephropathy Read Post »
Health TidingsIV Ketamine Outperformed Esketamine in NRx’s Real-World Depression St... IV Ketamine Outperformed Esketamine in NRx’s Real-World Depression St... Read Post »
GenericsLupin and Alembic Secure FDA Approvals, Expanding Indian Pharma’s U.S. Fo... Lupin and Alembic Secure FDA Approvals, Expanding Indian Pharma’s U.S. Fo... Read Post »
Health TidingsFDA Issues Complete Response Letter for Xspray’s Nilopki NDA FDA Issues Complete Response Letter for Xspray’s Nilopki NDA Read Post »
GenericsTeva Enters Ophthalmology With European Launch of AHZANTIVE Teva Enters Ophthalmology With European Launch of AHZANTIVE Read Post »
Health TidingsUCB and Biogen Present New Phase 3 Dapirolizumab Pegol Results in SLE UCB and Biogen Present New Phase 3 Dapirolizumab Pegol Results in SLE Read Post »
Health TidingsFDA Grants Breakthrough Therapy Designation to Biogen’s Salanersen for SM... FDA Grants Breakthrough Therapy Designation to Biogen’s Salanersen for SM... Read Post »
Health TidingsFDA Accepts Pharming’s Pediatric sNDA for Joenja® in APDS FDA Accepts Pharming’s Pediatric sNDA for Joenja® in APDS Read Post »
Health TidingsTerremoto Advances TER-2013 With FDA Fast Track Designation Terremoto Advances TER-2013 With FDA Fast Track Designation Read Post »
Health TidingsCingulate’s ADHD Drug CTx-1301 Hit with FDA Complete Response Letter Cingulate’s ADHD Drug CTx-1301 Hit with FDA Complete Response Letter Read Post »
GenericsApotex Launches Lower-Cost Sitagliptin Therapies for Type 2 Diabetes Apotex Launches Lower-Cost Sitagliptin Therapies for Type 2 Diabetes Read Post »
Health Tidings Mergers & AcquisitionsIDEAYA and Roche Advance PRMT5 and Pan-RAS Inhibitors in Pancreatic Cancer IDEAYA and Roche Advance PRMT5 and Pan-RAS Inhibitors in Pancreatic Cancer Read Post »
Health Tidings Mergers & AcquisitionsAscidian Secures Up to $1.9 Billion in Lilly Kidney Disease Partnership Ascidian Secures Up to $1.9 Billion in Lilly Kidney Disease Partnership Read Post »
Health TidingsKura Reports Early Success for Darlifarnib in KRAS-Mutant Solid Tumors Kura Reports Early Success for Darlifarnib in KRAS-Mutant Solid Tumors Read Post »
